WuXi Biologics and Prima Signs MOU and Announces Strategic Development and Manufacturing Partnership

SHANGHAI and SYDNEY --- WuXi Biologics and Prima Biomed Ltd. announce a non-binding MOU was signed to form a strategic biologics development and manufacturing partnership.

Under the partnership, WuXi Biologics will be the exclusive clinical manufacturer for IMP321 for Prima worldwide, excluding any manufacturing for the supply of China, Macau, Taiwan and Hong Kong where rights are retained by Prima's development partner in China, Eddingpharm. WuXi Biologics will also be Prima's preferred partner to manufacture potential new products.

IMP321, a first-in-class soluble LAG-3 Ig fusion protein and an APC activator boosting T cell responses for cancer chemo-immunotherapy is currently in Phase II trials in Europe.

CEO of Prima BioMed, Mr. Marc Voigt said, "Securing the future supply of IMP321 is a key component of our commercial development strategy. WuXi Biologics have consistently delivered the highest quality materials for our clinical trials. This MOU further strengthens our strategic partnership."

More info is available at:
http://www.wuxiapptec.com
http://www.wuxibiologics.com
http://www.primabiomed.com.au

Suggested Articles

Low-level autonomy vehicles will grow by 11% a year and there won’t be any produced at the highest autonomy before 2024, according to IDC.

Nvidia’s GPU Cloud hub will be integrated into vSphere, Cloud Foundation and Tanzu

Analyst firm sees yearly growth in use of 5G wireless used in comms and guidance for vehicles despite pandemic slowdown